Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TLSI TriSalus Life Sciences Inc
- Stocks
- Healthcare
- NASDAQ: TLSI
Price (delayed)
$5.16
Market cap
$195.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.12
Enterprise value
$215.37M
Highlights
TriSalus Life Sciences's quick ratio has soared by 175% YoY and by 18% from the previous quarter
TLSI's EPS has soared by 97% YoY and by 15% QoQ
TLSI's debt is up by 40% since the previous quarter
TriSalus Life Sciences's equity has decreased by 33% from the previous quarter
Key stats
What are the main financial stats of TLSI
Market
Valuations
Earnings
Shares outstanding
37.84M
Market cap
$195.25M
Enterprise value
$215.37M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.7
Revenue
$32.14M
Gross profit
$27.51M
Operating income
-$31.82M
Net income
-$27.21M
EBIT
-$22.91M
EBITDA
-$21.82M
Free cash flow
-$35.47M
Per share
Balance sheet
Liquidity
EPS
-$1.12
EPS diluted
-$1.12
Free cash flow per share
-$1.24
Book value per share
-$1.13
Revenue per share
$1.13
TBVPS
$1
Total assets
$28.63M
Total liabilities
$63M
Debt
$33.12M
Equity
-$34.37M
Working capital
$13.34M
Debt to equity
-0.96
Current ratio
2.14
Quick ratio
1.57
Net debt/EBITDA
-0.92
Margins
Efficiency
Dividend
EBITDA margin
-67.9%
Gross margin
85.6%
Net margin
-84.7%
Operating margin
-99%
Return on assets
-96.8%
Return on equity
N/A
Return on invested capital
-75.6%
Return on capital employed
-135.8%
Return on sales
-71.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TLSI stock price
How has the TriSalus Life Sciences stock price performed over time
Intraday
-0.58%
1 week
-7.36%
1 month
0.98%
1 year
-29.89%
YTD
2.99%
QTD
-6.52%
Financial performance
How have TriSalus Life Sciences's revenue and profit performed over time
Revenue
$32.14M
Gross profit
$27.51M
Operating income
-$31.82M
Net income
-$27.21M
Gross margin
85.6%
Net margin
-84.7%
TLSI's net margin has surged by 71% year-on-year and by 17% since the previous quarter
TLSI's operating margin has soared by 61% YoY and by 19% QoQ
TriSalus Life Sciences's net income has surged by 58% YoY and by 9% QoQ
The revenue is up by 46% year-on-year and by 9% since the previous quarter
Price vs fundamentals
How does TLSI's price correlate with its fundamentals
Growth
What is TriSalus Life Sciences's growth rate over time
Valuation
What is TriSalus Life Sciences stock price valuation
P/E
N/A
P/B
N/A
P/S
4.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.7
TLSI's EPS has soared by 97% YoY and by 15% QoQ
TriSalus Life Sciences's equity has decreased by 33% from the previous quarter
The revenue is up by 46% year-on-year and by 9% since the previous quarter
TLSI's P/S is 4% below its last 4 quarters average of 4.8
Efficiency
How efficient is TriSalus Life Sciences business performance
TLSI's ROS has soared by 76% YoY and by 22% QoQ
TriSalus Life Sciences's ROA has soared by 65% YoY and by 18% from the previous quarter
The return on invested capital is up by 41% since the previous quarter
Dividends
What is TLSI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TLSI.
Financial health
How did TriSalus Life Sciences financials performed over time
The company's total assets is 55% lower than its total liabilities
TriSalus Life Sciences's quick ratio has soared by 175% YoY and by 18% from the previous quarter
TLSI's current ratio has surged by 133% year-on-year and by 6% since the previous quarter
TLSI's debt is 196% greater than its equity
TLSI's debt is up by 40% since the previous quarter
TriSalus Life Sciences's equity has decreased by 33% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.